MitoQ is a modified coenzyme Q10 that concentrates inside mitochondria to neutralize damaging oxygen molecules. Its strongest human evidence is improved aging blood-vessel function, mainly in older or less-fit people, plus lower oxidative-damage markers. The most common downside is mild stomach upset, alongside an unresolved kidney-safety question. Long-term longevity benefit remains unproven. (Full Review)

Protocol

Dose

5–10 mg/day

Mitoquinol mesylate, single oral dose once daily

Timing

Morning, empty stomach

Often 30–60 minutes before food to aid modest absorption

Frequency

Once daily

Tissue retention supports once-daily dosing; no split dosing

Time to effect

Vascular Function

4–6 weeks

Endothelial and vascular changes emerge in trials

Oxidative Markers

4–6 weeks

Oxidative-damage markers decline over daily use

Longevity Benefit

Long-term

Inherently long-term and not directly felt

Benefits

Medium: Improved vascular endothelial function; reduced systemic and exercise-induced oxidative stress

Low: Reduced arterial stiffness; improved liver enzymes in chronic liver injury

Speculative: Reduced cellular senescence and healthy aging; cerebrovascular and cognitive support; skin and dermal aging

Contraindications

Pregnancy and breastfeeding (no safety data)

Children (not studied)

Chronic kidney disease, especially advanced (eGFR <30 mL/min/1.73 m²)

Key Interactions

Anticoagulants (warfarin)

Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers)

High-dose antioxidant vitamins (vitamin C, vitamin E)

Antioxidant/mitochondrial supplements (CoQ10, ubiquinol, PQQ, alpha-lipoic acid, N-acetylcysteine)

Vascular supplements (beetroot/nitrate, L-arginine, L-citrulline, magnesium)

Risk & Side Effects

Medium: Gastrointestinal effects

Low: Pro-oxidant and mitochondrial uncoupling at high doses; blunting of exercise training adaptations; kidney safety signal (conflicted)

Speculative: Unknown long-term safety; interference with adaptive redox signaling

Monitoring

Marker	Target	Why
Flow-mediated dilation (FMD)	>6–7%	Primary target; tracks endothelial function
Blood pressure	<120/80 mmHg	Downstream vascular outcome; may fall modestly
Oxidized LDL	Lower is better	Reflects oxidative damage to cholesterol
hs-CRP	<1.0 mg/L	General inflammation marker relevant to vascular aging
eGFR	>90 mL/min/1.73 m²	Kidney safety surveillance given nephrotoxicity signal
Serum creatinine	~0.6–1.1 mg/dL	Direct kidney-function marker paired with eGFR
ALT	<25 U/L (men), <20 U/L (women)	Liver-injury enzyme; MitoQ lowered it in liver disease
Arterial stiffness (pulse wave velocity)	<7.6 m/s	Secondary vascular target; benefit seen mainly if elevated

Cadence: Recheck at 8–12 weeks, then every 6–12 months during continued use; kidney function at least annually

Qualitative Assessment

Perceived energy and exercise tolerance during daily activity
Exercise recovery and post-exertion soreness
General sense of wellbeing and cognitive clarity
Any gastrointestinal symptoms signaling a need to adjust dose or timing

MitoQ for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment